/Companies

Renova Therapeutics

Carlsbad, US · 1 known investors

Find your way into Renova Therapeutics

50 people in our graph share verified history with the Renova Therapeutics team — schools, employers, funds. One of them is your warm intro.

Kirk Haneyunlockedknows Shawn Swaney · together at SG Biofuels (overlapped)
knows the team · via DivX
×2knows the team · via Novatel Wireless
×7knows the team · via Gateway
knows the team · via Renova Therapeutics

Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.

Founders & leadership

KH
Kirk HammondFounder
SSShawn Swaney
Shawn SwaneyChief Financial Officer and Chief Operating OfficerShawn Swaney is an Executive Officer at Renova Therapeutics and brings over three decades of finance leadership experience across technology and life-science companies, including roles supporting SaaS operations, capital raises exceeding $180 million, and large-scale acquisitions and expansions.

Board

RC
Roy CosanBoard director
PL
Pierre LecocqBoard director
VM
Vijay MahantBoard director
MT
Michael TorresBoard director
WD
William DavidsonBoard director
MX
Morgan XuBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$166.5K disclosed across 1 round · 2024

▶$166.5KraisedSep 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy CosanDirector
  • Pierre LecocqDirector
  • Vijay MahantDirector
  • Michael TorresDirector
  • Kirk HammondDirector
  • William DavidsonDirector
  • Morgan XuDirector
  • Shawn SwaneyExecutive Officer
Offering amount
$500K
Amount sold
$166.5K
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Companies competing with Renova Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase IISTTR2022$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2019$241.7K
National Institutes of Health (NIH)National Institutes of HealthPhase IISTTR2016$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2014$240.8K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Renova Therapeutics do?
Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.
Who founded Renova Therapeutics?
Renova Therapeutics was founded by Kirk Hammond.
Who are Renova Therapeutics's investors?
Renova Therapeutics's investors include BioBrit.
How much funding has Renova Therapeutics raised?
Renova Therapeutics has disclosed $166.5K raised across 1 round.
Where is Renova Therapeutics headquartered?
Renova Therapeutics is headquartered in Carlsbad, US.